Cipher Pharmaceuticals Inc. (FRA:PHE)

Market Cap	287.72M +50.2%
Revenue (ttm)	42.97M +51.2%
Net Income	23.28M +136.7%
EPS	0.89 +128.3%
Shares Out	n/a
PE Ratio	12.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	10.90
Previous Close	11.30
Day's Range	10.90 - 10.90
52-Week Range	6.95 - 11.90
Beta	n/a
RSI	55.46
Earnings Date	May 7, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PHE

Financial Performance

In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.

Financial numbers in USD